Heparin Sodium Injection is indicated for anticoagulant therapy. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. It acts at multiple sites in the normal coagulation system. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.
Heparin Sodium is supplied in the Company’s Simplist ready-to-administer prefilled syringes. It provides clear and consistent labeling, individual barcodes on both packaging and syringes, and requires no assembly or point-of care preparation. The Simplist packaging can help reduce medication errors by eliminating drug preparation steps and vial-to-syringe transfers.